Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 47.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 349,591 shares of the company’s stock after selling 313,794 shares during the period. Squarepoint Ops LLC’s holdings in Ginkgo Bioworks were worth $117,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of DNA. Vanguard Group Inc. raised its position in shares of Ginkgo Bioworks by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 132,780,095 shares of the company’s stock worth $224,398,000 after acquiring an additional 463,096 shares during the period. B. Riley Wealth Advisors Inc. raised its position in shares of Ginkgo Bioworks by 63.8% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 189,646 shares of the company’s stock worth $321,000 after acquiring an additional 73,843 shares during the period. Green Alpha Advisors LLC raised its position in shares of Ginkgo Bioworks by 47.5% in the first quarter. Green Alpha Advisors LLC now owns 297,637 shares of the company’s stock worth $345,000 after acquiring an additional 95,842 shares during the period. Salem Investment Counselors Inc. raised its position in shares of Ginkgo Bioworks by 110.6% in the first quarter. Salem Investment Counselors Inc. now owns 4,758,585 shares of the company’s stock worth $5,520,000 after acquiring an additional 2,499,425 shares during the period. Finally, Quattro Financial Advisors LLC raised its position in shares of Ginkgo Bioworks by 8,749,900.0% in the first quarter. Quattro Financial Advisors LLC now owns 175,000 shares of the company’s stock worth $203,000 after acquiring an additional 174,998 shares during the period. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

DNA stock opened at $7.33 on Monday. The stock has a market capitalization of $407.40 million, a price-to-earnings ratio of -0.40 and a beta of 1.10. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $75.20.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($3.20) EPS for the quarter, meeting analysts’ consensus estimates of ($3.20). The company had revenue of $56.21 million during the quarter, compared to the consensus estimate of $41.46 million. Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. On average, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on DNA. The Goldman Sachs Group reduced their price target on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating for the company in a research report on Tuesday, July 9th. BTIG Research upped their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. Finally, TD Cowen upped their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and an average price target of $4.16.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.